hepatocellular carcinoma	is a type of	liver cancer
intrahepatic cholangiocarcinoma	is a type of	liver cancer
combined hepatocellular-cholangiocarcinoma	is a type of	liver cancer
fibrolamellar hepatocellular carcinoma	is a type of	hepatocellular carcinoma
liver cancer	is a malignant neoplasm of	liver
cirrhosis	is a risk factor for	liver cancer
hepatitis B virus infection	is a risk factor for	liver cancer
hepatitis C virus infection	is a risk factor for	liver cancer
alcohol use disorder	is a risk factor for	liver cancer
nonalcoholic fatty liver disease	is a risk factor for	liver cancer
diabetes mellitus	is a risk factor for	liver cancer
aflatoxin exposure	is a risk factor for	liver cancer
obesity	is a risk factor for	liver cancer
smoking	is a risk factor for	liver cancer
age	is a risk factor for	liver cancer
male sex	is a risk factor for	liver cancer
hemochromatosis	is a risk factor for	liver cancer
bile duct disease	is a risk factor for	intrahepatic cholangiocarcinoma
liver cirrhosis	is a risk factor for	intrahepatic cholangiocarcinoma
smoking	is a risk factor for	intrahepatic cholangiocarcinoma
age	is a risk factor for	intrahepatic cholangiocarcinoma
diabetes mellitus	is a risk factor for	intrahepatic cholangiocarcinoma
alpha-fetoprotein	is a tumor marker for	hepatocellular carcinoma
des-gamma-carboxy prothrombin	is a tumor marker for	hepatocellular carcinoma
CA19-9	is a tumor marker for	intrahepatic cholangiocarcinoma
CA19-9	is a tumor marker for	liver cancer
MRI	is a diagnostic method for	liver cancer
CT scan	is a diagnostic method for	liver cancer
ultrasound	is a diagnostic method for	liver cancer
liver biopsy	is a diagnostic method for	liver cancer
histology	confirms	hepatocellular carcinoma
histology	confirms	intrahepatic cholangiocarcinoma
imaging	is used for	liver cancer diagnosis
surgery	is a treatment for	liver cancer
hepatectomy	is a treatment for	liver cancer
liver transplantation	is a treatment for	liver cancer
ablation	is a treatment for	liver cancer
radiofrequency ablation	is a treatment for	liver cancer
microwave ablation	is a treatment for	liver cancer
transarterial chemoembolization	is a treatment for	liver cancer
transarterial embolization	is a treatment for	liver cancer
embolization	is a treatment for	liver cancer
systemic chemotherapy	is a treatment for	liver cancer
sorafenib	is a drug used for	liver cancer
lenvatinib	is a drug used for	liver cancer
regorafenib	is a drug used for	liver cancer
cabozantinib	is a drug used for	liver cancer
atezolizumab-bevacizumab	is a therapy for	hepatocellular carcinoma
nivolumab	is a therapy for	hepatocellular carcinoma
pembrolizumab	is a therapy for	hepatocellular carcinoma
immunotherapy	is a therapy for	liver cancer
radiation therapy	is a therapy for	liver cancer
palliative care	is a care for	liver cancer
clinical trial	is an option for	liver cancer
vascular invasion	predicts	recurrence after liver cancer treatment
tumor size	predicts	survival in liver cancer
number of nodules	predicts	prognosis in liver cancer
multifocality	predicts	prognosis in liver cancer
child-pugh score	predicts	liver cancer outcomes
MELD score	predicts	liver cancer outcomes
alpha-fetoprotein level	correlates with	prognosis in hepatocellular carcinoma
stage	determines	prognosis in liver cancer
vascular invasion	increases	recurrence risk in liver cancer
tumor margins	influence	surgical outcome in liver cancer
performance status	predicts	treatment tolerance in liver cancer
bilirubin level	predicts	prognosis in liver cancer
albumin level	predicts	prognosis in liver cancer
platelet count	predicts	bleeding risk in liver cancer surgery
portal hypertension	accompanies	cirrhosis
ascites	indicates	advanced liver cancer
cachexia	occurs with	advanced liver cancer
paraneoplastic syndrome	may accompany	liver cancer
fever	occurs with	infection in liver cancer
liver function tests	monitor	liver cancer progression
imaging follow-up	monitors	liver cancer progression
surveillance imaging	monitors	liver cancer recurrence
tumor progression	indicates	treatment escalation in liver cancer
surgical candidacy	depends on	liver function
transplant eligibility	depends on	tumor burden in liver cancer
ALBI score	predicts	survival in liver cancer
bilirubin clearance	indicates	liver function after resection
portal vein thrombosis	worsens	prognosis in liver cancer
hepatic venous outflow	affects	liver surgery risk
cirrhotic liver remnant	influences	postoperative outcome
recovery after surgery	is influenced by	liver function
infection after surgery	increases	mortality risk in liver cancer
postoperative liver failure	is a complication of	liver cancer surgery
recurrence after resection	occurs with	hepatocellular carcinoma
recurrence after transplant	occurs with	hepatocellular carcinoma
tumor marker decline	indicates	treatment response in liver cancer
radiologic response	indicates	treatment response in liver cancer
biopsy findings	guide	treatment choice in liver cancer
multidisciplinary tumor board	coordinates	liver cancer care
antifibrotic therapy	may reduce	liver cancer risk
antiviral therapy	reduces	risk of liver cancer in hepatitis B or C
HBV vaccination	reduces	liver cancer incidence
HBV suppression	reduces	hepatitis B reactivation during therapy
liver function reserve	limits	surgical options
portal venous pressure	influences	surgical planning in liver cancer
hepatocellular carcinoma	is a	liver cancer
intrahepatic cholangiocarcinoma	is a	liver cancer
hepatocellular carcinoma	is a	malignant liver tumor
intrahepatic cholangiocarcinoma	is a	malignant biliary tumor
cirrhosis	increases risk of	hepatocellular carcinoma
cirrhosis	associated with	portal hypertension
obesity	increases risk of	hepatocellular carcinoma
diabetes mellitus	increases risk of	hepatocellular carcinoma
alcohol consumption	increases risk of	hepatocellular carcinoma
nonalcoholic fatty liver disease	increases risk of	hepatocellular carcinoma
hepatitis C infection	increases risk of	hepatocellular carcinoma
hepatitis B infection	increases risk of	hepatocellular carcinoma
primary sclerosing cholangitis	increases risk of	intrahepatic cholangiocarcinoma
liver fluke infection	increases risk of	cholangiocarcinoma
bile duct stones	associated with	cholangiocarcinoma
age	associated with	hepatocellular carcinoma
male sex	associated with	hepatocellular carcinoma
family history of liver cancer	increases risk of	hepatocellular carcinoma
hepatocellular carcinoma	associated with	vascular invasion
intrahepatic cholangiocarcinoma	associated with	biliary invasion
alpha-fetoprotein	is biomarker for	hepatocellular carcinoma
alpha-fetoprotein	is elevated in	hepatocellular carcinoma
CA 19-9	is biomarker for	intrahepatic cholangiocarcinoma
CA 19-9	is elevated in	intrahepatic cholangiocarcinoma
liver biopsy	used for	confirmation of hepatocellular carcinoma
imaging	used for	diagnosis of hepatocellular carcinoma
CT scan	used for	diagnosis of hepatocellular carcinoma
MRI	used for	diagnosis of hepatocellular carcinoma
biopsy	used for	confirmation of intrahepatic cholangiocarcinoma
imaging	used for	diagnosis of intrahepatic cholangiocarcinoma
CT scan	used for	diagnosis of intrahepatic cholangiocarcinoma
MRI	used for	diagnosis of intrahepatic cholangiocarcinoma
liver cancer	diagnosed by	imaging
hepatocellular carcinoma	treated with	surgical resection
hepatocellular carcinoma	treated with	liver transplantation
hepatocellular carcinoma	treated with	transarterial chemoembolization
hepatocellular carcinoma	treated with	radiofrequency ablation
hepatocellular carcinoma	treated with	microwave ablation
hepatocellular carcinoma	treated with	systemic therapy
hepatocellular carcinoma	treated with	sorafenib
hepatocellular carcinoma	treated with	lenvatinib
hepatocellular carcinoma	treated with	immunotherapy
intrahepatic cholangiocarcinoma	treated with	surgical resection
intrahepatic cholangiocarcinoma	treated with	chemotherapy
intrahepatic cholangiocarcinoma	treated with	radiotherapy
intrahepatic cholangiocarcinoma	treated with	biliary drainage
intrahepatic cholangiocarcinoma	treated with	systemic therapy
liver cancer	treated with	locoregional therapy
sorafenib	used for	hepatocellular carcinoma
gemcitabine	used with	cisplatin
cisplatin	used with	gemcitabine
immunotherapy	used in	hepatocellular carcinoma
targeted therapy	used in	hepatocellular carcinoma
immunotherapy	used in	intrahepatic cholangiocarcinoma
radiotherapy	used in	intrahepatic cholangiocarcinoma
palliation	provided by	transarterial chemoembolization
palliative care	relevant to	advanced liver cancer
surgical resection	improves	overall survival
liver transplantation	improves	overall survival in select hepatocellular carcinoma
locoregional therapy	provides	disease control in hepatocellular carcinoma
chemotherapy	provides	symptom relief in cholangiocarcinoma
tumor burden	influences	prognosis
portal vein thrombosis	worsens	prognosis in hepatocellular carcinoma
liver dysfunction	complicates	management of hepatocellular carcinoma
hepatic reserve	limits	curative therapy for hepatocellular carcinoma
child-pugh score	guides	treatment selection in hepatocellular carcinoma
staging system	determines	prognosis of hepatocellular carcinoma
treatment response	predicts	survival in hepatocellular carcinoma
radiologic response	correlates with	disease control
surgical margin status	predicts	recurrence after resection
vascular invasion	associated with	poor prognosis in hepatocellular carcinoma
intrahepatic cholangiocarcinoma	often presents with	weight loss
intrahepatic cholangiocarcinoma	often presents with	jaundice
intrahepatic cholangiocarcinoma	associated with	pruritus
intrahepatic cholangiocarcinoma	associated with	cholestasis
liver cancer	associated with	portal hypertension
postoperative mortality	risk with	cirrhosis
diabetes mellitus	worsens	prognosis in hepatocellular carcinoma
nonalcoholic fatty liver disease	progresses to	cirrhosis
cirrhosis	reduces	hepatic reserve
hepatic reserve	limits	resection candidacy
alpha-fetoprotein	used to monitor	disease status in hepatocellular carcinoma
CA 19-9	used to monitor	disease status in cholangiocarcinoma
liver cancer	common in	older adults
cholangiocarcinoma	rare in	children
liver cancer	screen in	high-risk populations
safety profile	differs between	hepatocellular carcinoma therapies
treatment toxicity	varies with	liver function
renal function	influences	chemotherapy selection
liver cancer	recurrence after	resection
cirrhosis	complicates	liver cancer management
liver cancer	metastasizes to	lungs
hepatocellular carcinoma	metastasizes to	lungs
intrahepatic cholangiocarcinoma	metastasizes to	lymph nodes
hepatocellular carcinoma	metastasizes to	lymph nodes
hepatic stellate cell activation	contributes to	cirrhosis
liver cancer	etiology	multifactorial
cholangiocarcinoma	etiology	multifactorial
mixed hepatocellular-cholangiocarcinoma	classified as	rare tumor type
cirrhosis	surveillance with	ultrasound
